Atreca to Present at Upcoming Virtual Investor Conferences
09 September 2021 - 6:30AM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
that it will present at the following upcoming virtual investor
conferences:
HC Wainwright
23rd Annual Global Investment
ConferenceSeptember 13-15, 2021Presentation available
beginning September 13
Baird Global Healthcare
ConferenceSeptember 14-15, 2021Fireside chat time: 3:00
p.m. EDT, Wednesday, September 15
An audio webcast of the HC Wainwright presentation
will be available on-demand beginning at 7:00 a.m. Eastern Time on
September 13, 2021, and can be accessed through the Events &
Presentations section of the Company's website at ir.atreca.com.
The presentation will be available on the Company's website for 90
days.
About Atreca, Inc. Atreca is a
biopharmaceutical company developing novel antibody-based
immunotherapeutics generated by its differentiated discovery
platform. Atreca’s platform allows access to an unexplored
landscape in oncology through the identification of unique
antibody-target pairs generated by the human immune system during
an active immune response against tumors. These antibodies provide
the basis for first-in-class therapeutic candidates, such as our
lead product candidate ATRC-101. A Phase 1b study evaluating
ATRC-101 in multiple solid tumor cancers is currently enrolling
patients. For more information on Atreca, please visit
www.atreca.com.
Forward-Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, statements about our
plans, objectives, representations and contentions and typically
are identified by use of terms such as "continued," "anticipate,"
"potential," "expect," "believe," "planned," and similar words,
although some forward-looking statements are expressed differently.
These statements include those related to our strategy and future
plans, including statements regarding the development of ATRC-101
and our preclinical, clinical and regulatory plans and the timing
thereof. Our actual results may differ materially from those
indicated in these forward-looking statements due to risks and
uncertainties related to the initiation, timing, progress and
results of our research and development programs, preclinical
studies, clinical trials, regulatory submissions, and other matters
that are described in our filings with the Securities and Exchange
Commission (SEC) and available on the SEC’s website at www.sec.gov,
including in the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” sections
of our most recently filed annual report on Form 10-K and quarterly
report on Form 10-Q. Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release, and we undertake no obligation
to update any forward-looking statement in this press release,
except as required by law.
Contacts
Atreca, Inc.Herb CrossChief Financial
Officerinfo@atreca.comInvestors:Alex Gray, 650-779-9251, ext.
251agray@atreca.com
Media:Sheryl Seapy,
213-262-9390sseapy@w2ogroup.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024